西洛他唑对冠心病合并2型糖尿病患者脂代谢的影响

目的 观察西洛他唑(CS)对冠心痛(CHD)合并2型糖尿病(2DM)患者脂代谢的影响.方法 80例CHD合并2-DM患者随机分为2组,A组:普伐他汀20 mg每晚1次.B组:普伐他汀20mg每晚1次 西洛他唑50 mg,每日2次;另设健康对照组38例,治疗并随访6个月.于入院第2天及治疗3个月后检测血脂水平.结果 3个月后A、B 2组总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)较治疗前降低(P<0.05);B组高密度脂蛋白胆固醇(HDLC)较治疗前明显升高(P<0.01),TC、LDL-C与A组比较差异无统计学意义(P>0.05),TC显著低于A组,HDL-C显著升高(P<0.01).B组冠心病加重百分率较A组降低(P<0.05).结论 西洛他唑可降低CHD合并2DM患者的TG水平,并提升HDL-C水平,改善预后.

Effect of cilostazol on lipids metabolism in patients with coronary heart disease complicated with 2-diabetes mellitus

Objective To study the effect of cilostazol on lipids metabolism in patients with coronary heart disease(CHD) complicated with 2-diabetes mellitus(2-DM).Methods A total of 80 patients with CHD complicated with 2-DM were divided into two groups randomly.Group A received 20 mg of pravastain every night for 6 months.Group B received 50 mg of cilostazol per 12 hours for 6 months besides of pravastain.Meanwhile,38 cases of heathly people were as the control group.The serum levels of lipids were determined at second day and 3 months later.Results The serum levels of total cholesterol(TC),triglyceride(TG) and low density lipoprotein cholesterol(LDL-C) in both groups decreased significantly after 3 months therapy(P<0.01).The serum levels of high density lipoprotein cholesterol(HDL-C) of group B raised significantly than before treatment(P<0.01).Compared with group A,the levels of TC,LDL-C in group B were no differences(P>0.05),and the TG level was lower and the HDL-C was higher significantly(P<0.01).In addition,the rate of deteriorated CHD was lower than that of group A(P<0.05).Conclusion Cilostazol can decrease the serum TG level and raise the serum HDL-C level,suggesting it can improve the outcome of patients with coronary heart disease complicated with 2-diabetes mellitus.